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ABSTRACT
INTRODUCTION: Multiple Endocrine Neoplasia (MEN) is a rare autosomal dominant disease with frequen-
cy 1:30 000 and it is classified in 3 subtypes: MEN 2A (Sipple syndrome), familial medullary thyroid carci-
noma (FMTC), MEN 2B. The MEN 2A subtype constitutes approximately 70%-80% of cases of MEN 2.  The 
onset age of the MEN 2A is prior to age 35 years. MEN 2A has an increased risk for parathyroid hyperpla-
sia or adenoma. The clinical diagnosis is suspected when at least 2 specific endocrine tumors are detected in 
one patient or close relatives (MTC, pheochromocytoma, parathyroid adenomas). MTC is suspected in case 
of increased serum levels of calcitonin. The biochemical phenotype of MTC is revealed between age 5 and 
25 (mean age 15 years). The tumor formation in the neck area is between age of 15 and 20. Although there is 
controversy surrounding the definition of C-Cell Hyperplasia (CCH), its utility to identify or confirm MEN 
2 has been essentially replaced by RET (REarranged during Transfection) protooncogene testing. This al-
lows the early surgery interventions, proper genetic counseling and prenatal diagnostics.
MATERIAL AND METHODS: We report on a Caucasian male with complains of general weakness and 
weight loss (10 kg for 2 month). The patient’s mother has been diagnosed at 47 as bilateral pheochromocyto-
mas and struma nodosa and died at age of 51. In the index patient abdominal ultrasound examination with 
biopsy of adrenal glands and histological analysis revealed pheochromocytoma on the right side; elevated 
plasma calcitonin concentration and US scan with biopsy of thyroid tissue detected medular thyroid cancer. 
The index patient has two elder brothers – it turned out that one of them had been surgically treated for me-
dular thyroid cancer in the past; bilateral pheocromocytomas were detected in the family screening process. 
Scripta Scientifica Medica, vol. 47, No 2, 2015, pp. 72-75 
Copyright © Medical University of Varna   73
Andrey Kirov, Tihomir Todorov, Lyudmila Angelova et al.
INTRODUCTION 
Multiple Endocrine Neoplasia (MEN) is a rare 
autosomal dominant disease with frequency 1:30 
000 and it is classified in 3 subtypes: MEN 2A (Sip-
ple syndrome), familial medullary thyroid carcino-
ma (FMTC) and MEN 2B (1). The MEN 2A subtype 
constitutes approximately 70%-80% of cases of MEN 
2 (1). The onset age of the MEN 2A is prior to age 35 
years. MEN 2A has an increased risk for parathyroid 
hyperplasia or adenoma. MEN 2A is diagnosed clin-
ically by the occurrence of at least two specific en-
docrine tumors (medullary carcinoma of the thyroid 
– MTC, pheochromocytoma or parathyroid adeno-
ma/hyperplasia) in a single individual or in close rel-
atives (1). MTC is suspected in case of increased se-
rum levels of calcitonin. It is the principal biochemi-
cal marker in MTC; it is used for detection, staging, 
postoperative management, and prognosis. The in-
creased excretion of catecholamine metabolites dur-
ing urinalysis is a biochemical marker for pheochro-
mocytoma. The biochemical phenotype of MTC is 
revealed between age 5 and 25 (mean age 15 years). 
Parathormone plasma level is elevated in parathyroid 
hyperplasia or adenoma. Unusual blood levels of cal-
cium and phosphorus may also suggest one of these. 
They may be suspected also in case of decrease in 
bone density or kidney stones. 
Biochemical testing via measurement of plasma 
free metanephrines or urinary fractionated meta-
nephrines should be performed in patients suspect-
ed of having pheochromocytoma or paraganglioma 
(PPGL) (2)  The tumor formation in the neck area in 
MTC is between age of 15 and 20 (3). 
Affected individuals initially develop prima-
ry C-cell hyperplasia (CCH) that progresses to early 
invasive medullary microcarcinoma, and eventual-
ly develop grossly invasive macroscopic MTC. MTC 
originates in calcitonin-producing cells (C-cells) of 
the thyroid gland. REarranged during Transfection 
(RET) gene mutations cause abnormal proliferation 
and differentiation of the C-cells of the thyroid and 
the adrenal medulla (4). As CCH is a histological di-
agnosis, supplementing finding in thyroid pathology, 
the identification or confirmation of MEN 2 has been 
essentially based on RET sting (5). The gene is local-
ized on chromosome 10 (10q11.2). The genetic testing 
could confirm the clinical diagnosis, but it can also 
detect presymptomatic carriers of RET gene muta-
tions in index patient relatives. This allows proper ge-
netic counseling, prenatal diagnostics and early sur-
gery interventions in familial carrier members.
In the vast majority of cases (95%), MEN 2A is 
caused by mutations affecting cysteine residues in 
exon 10 (Codons 609, 611, 618, and 620) and 11 (most 
commonly, codon 634 – it is detected in 85% of the 
patients) of the RET gene (1). The codon 634 muta-
tion was recently reported as the second most com-
mon cause in Greece MTC patients (4).
Mutations in the RET codon 634 are caus-
ative of cutaneous lichen amyloidosis in some MEN 
2A = FMTC families (6). The RET gene mutations 
have high penetrance (85%); patients develop pheo-
chromocytoma in 50% and hyperparathyroidism in 
20-30%.
MATERIAL AND METHODS
We report on a Caucasian male of 35 years with 
complains of general weakness and weigh loss (10 kg 
for 2 month) admitted to the Endocrinologic clinics, 
University hospital St. Marina, Varna. In the index 
RESULTS AND CONCLUSION: MEN 2A diagnosis was suspected and we performed sequencing of RET pro-
tooncogene. The genetic analysis of the family affected members revealed c.1902C>G, p.Cys634Trp hetero-
zygous mutation. Unfortunately, two kids in the families of 2 of the brothers have also inherited the muta-
tion. All adult family members were offered genetic counseling. The standard therapy and the prophylactic 
thyroidectomy include the surgical removal of the thyroid gland, followed by parathyroid gland autotrans-
plantation. In case codon 634 mutation the surgery is recommended before age of 5 years. All affected rel-
atives are going through monitoring for residual disease. The screening protocol includes plasma levels of 
calcitonin. The stimulation tests are more sensitive than calcitonin measurements alone so they are recom-
mended.
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patient abdominal ultrasound examination with bi-
opsy of adrenal glands and histological analysis re-
vealed pheochromocytoma on right side; elevated 
plasma calcitonin concentration and US scan with 
biopsy of thyroid tissue detected medular thyroid 
cancer. Familial history and medical documentation 
showed that the patient’s mother has been diagnosed 
at 47 as bilateral pheochromocytomas and struma 
nodosa and died at age of 51. The index patient has 
two elder brothers – 40 and 42 years old (Fig. 1). It 
turned out that one of them (II 1-4) has been sur-
gically treated for MTC in the past, when hormone 
substitution therapy was prescribed. Bilateral pheo-
chromocytomas were detected in him during the 
family screening process. Mild fatigue had started 
in the oldest brother (II 1-5) and right pheochromo-
cytoma and MTC were diagnosed at the time of the 
familial investigation. Almost preclinical identifica-
tion of at-risk siblings led to the diagnosis of MTC 
and right sided pheocromocytoma in him.  
DNA from the index patient and his family (his 
son of 16 and his kniece of 7 encl.) were extracted 
through standard salt-precipitation protocol and the 
molecular-genetic testing of the RET gene was per-
formed in order to confirm the clinically suspect-
ed MEN 2A diagnosis. All exons and exon-intron 
boundaries of the RET gene were amplified through 
PCR (primers sequence are available upon request), 
followed by Sanger sequenced using BigDye Ter-
minator v.3.1 (Applied Biosystems, Foster City, CA, 
USA).
RESULTS AND DISCUSSION
MEN 2A diagnosis was suspected based on the 
phenotype data and the autosomal manner of inher-
itance high risk of recurrence (50%). A de novo gene 
mutation is only 5% or less in index cases with MEN 
2A. In our family all five first degree relatives descen-
dants of the ancestor were affected.  The clinical phe-
notype of the familial members and their treatment 
are described by Hristozov et al, 2013 (7). The disease 
is associated with RET protooncogene mutation so 
the index patient, all of his brothers and the two chil-
dren (patients ID 1-3, 1-4, 1-5, 1-6, 1-7) were referred 
for genetic testing of the RET gene. All adult family 
members were offered genetic counseling.  
The molecular-genetic testing confirmed the 
clinical diagnosis of MEN 2A. The genetic anal-
ysis of the family affected members and their chil-
dren showed a heterozygous mutation c.1902C>G, 
p.Cys634Trp in exon 11 of the RET gene in all of 
them (Figures 1 and 2). 
Germline mutations in RET protooncogene 
have been identified as the underlying cause MEN 
2 syndromes and FMTC. This gene encodes for a ty-
rosine kinase receptor that is only expressed in neu-
ral crest-derived tissues (8). Mutation in one of five 
codons for cysteine in extracellular domain (codons 
609, 618, 620, 630 and 634) in exons 10 and 11 oc-
curs in MEN2A and FMTC. Other mutations less 
frequently associated with these phenotypes occur in 
exons 13, 14 and 15. To date there are no specific mu-
tations responsible only for development of FMTC or 
MEN 2A phenotype. However, risk for pheochromo-
cytoma in patients with MEN 2A has been associated 
with any mutation of codon 634 (8).
The molecular-genetic testing showed that all 
tested relatives (ID 1-3 to 1-7) are carriers of the fam-
ily mutation. Both children (ID 1-6 and 1-7) are as-
Fig. 1. Family tree of the patient
Fig. 2. Result from RET gene molecular genetic testing of 
the index patient (ID 1-3)
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ymptomatic at the moment and they will go through 
periodical medical examinations. First, Schuffeneck-
er et al. (9) suggested that all codon 634 mutation car-
riers are at some risk for hyperparathyroidism and 
should be screened for this disease. The controver-
sial question for total thyroidectomy is still open, but 
the fact that 95% of individuals with MEN 2A (9) de-
velop MTC strongly indicates it. Moreover, bilater-
al or multifocal areas of MTC and C-cell hyperpla-
sia are usually observed at the time of thyroidecto-
my in affected individuals undergoing prophylactic 
thyroidectomy (10). As far as pheochromocytomas 
usually present after MTC a long term follow-up and 
extensive screening protocol is needed to determine 
the correct phenotype and improve patient clinical 
management. 
The standard therapy and the prophylactic thy-
roidectomy include the surgical removal of the thy-
roid gland, followed by parathyroid gland autotrans-
plantation (3). In case of codon 634 mutation the sur-
gery is recommended before age of 5 years. All affect-
ed relatives are going through monitoring for resid-
ual disease. The screening protocol includes plasma 
levels of calcitonin. The stimulation tests are more 
sensitive than calcitonin measurements alone so they 
are recommended. 
In case of normal screening results for pheo-
chromocytoma the tests are performed once per 
year, followed by MRI in case of abnormal results. 
Abdominal US and CT scan are also recommended 
as well as screening for parathyroid adenomas once 
per year (2,3). 
Our results allowed classifying the family as 
MEN 2A, thereby improving clinical management 
of family members. MEN 2A provides unique model 
for early prevention of cancer and for stratified roles 
of mutation-based diagnosis of carriers. Molecular-
genetic analysis of MEN 2A provides families with 
early genetic counseling information (possibilities 
for prenatal diagnosis included) in high risk domi-
nant cancer predisposing diseases.   
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